Gain Therapeutics Inc
Research Gain Therapeutics Inc (GANX) on Bullrun: market cap USD 82.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGANX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 82.56M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 21.24M
- Free cash flow-USD 19.37M
Valuation Snapshot
latest market cap is USD 82.56M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 20.16M | -USD 18.47M | n/a | -0.61 | USD 20.84M | USD 400.95K | USD 18.56M |
| FY2024 | USD 0 | -USD 20.41M | -USD 18.90M | n/a | -0.89 | USD 10.39M | USD 438.50K | USD 7.34M |
| FY2023 | USD 55.18K | -USD 22.27M | -USD 18.88M | n/a | -1.71 | USD 11.79M | USD 567.85K | USD 12.58M |
| FY2022 | USD 132.64K | -USD 17.59M | -USD 14.81M | n/a | -1.48 | USD 7.31M | USD 603.39K | USD 18.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 82.56M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 135.48M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 58.61M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 52.97M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 37.20M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 64.53M | n/a | n/a | n/a |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gain Therapeutics Inc's market cap?
Gain Therapeutics Inc's market capitalization is USD 82.56M.
What does Gain Therapeutics Inc do?
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation.